Evaluation of 5-year imatinib treatment of 458 patients with
CP-CML in routine clinical practice and prognostic impact of
different BCR-ABL cutoff levels.

J 2013

Evaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cutoff levels.

KLAMOVÁ, Hana, Kateřina MACHOVÁ POLÁKOVÁ, Jan MUŽÍK, Zdeněk RÁČIL, Daniela ŽÁČKOVÁ et. al.

Basic information

Original name

Evaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cutoff levels.

Authors

KLAMOVÁ, Hana (203 Czech Republic, guarantor), Kateřina MACHOVÁ POLÁKOVÁ (203 Czech Republic), Jan MUŽÍK (203 Czech Republic, belonging to the institution), Zdeněk RÁČIL (203 Czech Republic, belonging to the institution), Daniela ŽÁČKOVÁ (203 Czech Republic, belonging to the institution), Kateřina STEINEROVÁ (203 Czech Republic), Michal KARAS (203 Czech Republic), Edgar FABER (203 Czech Republic), Eva DEMEČKOVÁ (703 Slovakia), Zuzana MICHALOVIČOVÁ-SNINSKÁ (703 Slovakia), Jaroslava VOGLOVÁ (203 Czech Republic), Ludmila DEMITROVIČOVÁ (703 Slovakia), Eva MIKUŠOVÁ (703 Slovakia), Elena TÓTHOVÁ (703 Slovakia), Juraj CHUDEJ (703 Slovakia), Imrich MARKULJAK (703 Slovakia), Eduard CMUNT (203 Czech Republic), Jana MORAVCOVÁ (203 Czech Republic), Dana DVOŘÁKOVÁ (203 Czech Republic), Kyra MICHALOVÁ (203 Czech Republic), Marie JAROŠOVÁ (203 Czech Republic), Markéta MARKOVÁ ŠŤASTNÁ (203 Czech Republic), Petr CETKOVSKÝ (203 Czech Republic), Ladislav DUŠEK (203 Czech Republic, belonging to the institution), Vladimír KOZA (203 Czech Republic), Marek TRNĚNÝ (203 Czech Republic) and Karel INDRÁK (203 Czech Republic)

Edition

Cancer Medicine, Houston, John Wiley & Sons Ltd. 2013, 2045-7634

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

RIV identification code

RIV/00216224:14110/13:00069003

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1002/cam4.59

UT WoS

000209210600010

Keywords in English

BCR-ABL ratios; CML; ELN definitions; imatinib

Abstract

V originále

We evaluated responses to the treatment and long-term outcomes of chronic myeloid leukemia patients treated with imatinib as first-line treatment in routine clinical setting from two countries with centralized tyrosine kinase inhibitors (TKIs) treatment. We assessed prognostic significance of European LeukemiaNet (ELN) 2006- and 2009-defined responses and the prognostic value of molecular responses at defined time points on 5-year survivals. The ELN optimal response criteria and their predictive role were significantly beneficial for event-free survival at all given time points. We found significant improvement in survivals of patients with BCR-ABL lower than 10% in the 6th and 12th months. Significantly better outcome was found in patients who achieved major molecular response (MMR) in the 12th month. The cumulative incidences of complete cytogenetic response (CCyR) and MMR were significantly associated with the molecular response in the 3rd month. The ELN response criteria and their predictive role were helpful at given time points; however, the 2009 definition did not significantly alter the prognostic accuracy compared with that of the 2006 definition. The significant value was observed for cytogenetic responses at the 6th and 12th month. Moreover, progression-free and event-free survivals were improved with MMR at the 12th month.

Citovat

KLAMOVÁ, Hana, Kateřina MACHOVÁ POLÁKOVÁ, Jan MUŽÍK, Zdeněk RÁČIL, Daniela ŽÁČKOVÁ, Kateřina STEINEROVÁ, Michal KARAS, Edgar FABER, Eva DEMEČKOVÁ, Zuzana MICHALOVIČOVÁ-SNINSKÁ, Jaroslava VOGLOVÁ, Ludmila DEMITROVIČOVÁ, Eva MIKUŠOVÁ, Elena TÓTHOVÁ, Juraj CHUDEJ, Imrich MARKULJAK, Eduard CMUNT, Jana MORAVCOVÁ, Dana DVOŘÁKOVÁ, Kyra MICHALOVÁ, Marie JAROŠOVÁ, Markéta MARKOVÁ ŠŤASTNÁ, Petr CETKOVSKÝ, Ladislav DUŠEK, Vladimír KOZA, Marek TRNĚNÝ and Karel INDRÁK. Evaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cutoff levels. Cancer Medicine. Houston: John Wiley & Sons Ltd., 2013, vol. 2, No 2, p. 216-225. ISSN 2045-7634. Available from: https://dx.doi.org/10.1002/cam4.59.

@article{1119313,
   author = {Klamová, Hana and Machová Poláková, Kateřina and Mužík, Jan and Ráčil, Zdeněk and Žáčková, Daniela and Steinerová, Kateřina and Karas, Michal and Faber, Edgar and Demečková, Eva and MichalovičováandSninská, Zuzana and Voglová, Jaroslava and Demitrovičová, Ludmila and Mikušová, Eva and Tóthová, Elena and Chudej, Juraj and Markuljak, Imrich and Cmunt, Eduard and Moravcová, Jana and Dvořáková, Dana and Michalová, Kyra and Jarošová, Marie and Marková Šťastná, Markéta and Cetkovský, Petr and Dušek, Ladislav and Koza, Vladimír and Trněný, Marek and Indrák, Karel},
   article_location = {Houston},
   article_number = {2},
   doi = {http://dx.doi.org/10.1002/cam4.59},
   keywords = {BCR-ABL ratios; CML; ELN definitions; imatinib},
   language = {eng},
   issn = {2045-7634},
   journal = {Cancer Medicine},
   title = {Evaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cutoff levels.},
   volume = {2},
   year = {2013}
}

TY  - JOUR
ID  - 1119313
AU  - Klamová, Hana - Machová Poláková, Kateřina - Mužík, Jan - Ráčil, Zdeněk - Žáčková, Daniela - Steinerová, Kateřina - Karas, Michal - Faber, Edgar - Demečková, Eva - Michalovičová-Sninská, Zuzana - Voglová, Jaroslava - Demitrovičová, Ludmila - Mikušová, Eva - Tóthová, Elena - Chudej, Juraj - Markuljak, Imrich - Cmunt, Eduard - Moravcová, Jana - Dvořáková, Dana - Michalová, Kyra - Jarošová, Marie - Marková Šťastná, Markéta - Cetkovský, Petr - Dušek, Ladislav - Koza, Vladimír - Trněný, Marek - Indrák, Karel
PY  - 2013
TI  - Evaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cutoff levels.
JF  - Cancer Medicine
VL  - 2
IS  - 2
SP  - 216-225
EP  - 216-225
PB  - John Wiley & Sons Ltd.
SN  - 20457634
KW  - BCR-ABL ratios
KW  - CML
KW  - ELN definitions
KW  - imatinib
N2  - We evaluated responses to the treatment and long-term outcomes of chronic myeloid leukemia patients treated with imatinib as first-line treatment in routine clinical setting from two countries with centralized tyrosine kinase inhibitors (TKIs) treatment. We assessed prognostic significance of European LeukemiaNet (ELN) 2006- and 2009-defined responses and the prognostic value of molecular responses at defined time points on 5-year survivals. The ELN optimal response criteria and their predictive role were significantly beneficial for event-free survival at all given time points. We found significant improvement in survivals of patients with BCR-ABL lower than 10% in the 6th and 12th months. Significantly better outcome was found in patients who achieved major molecular response (MMR) in the 12th month. The cumulative incidences of complete cytogenetic response (CCyR) and MMR were significantly associated with the molecular response in the 3rd month. The ELN response criteria and their predictive role were helpful at given time points; however, the 2009 definition did not significantly alter the prognostic accuracy compared with that of the 2006 definition. The significant value was observed for cytogenetic responses at the 6th and 12th month. Moreover, progression-free and event-free survivals were improved with MMR at the 12th month.
ER  -

KLAMOVÁ, Hana, Kateřina MACHOVÁ POLÁKOVÁ, Jan MUŽÍK, Zdeněk RÁČIL, Daniela ŽÁČKOVÁ, Kateřina STEINEROVÁ, Michal KARAS, Edgar FABER, Eva DEMEČKOVÁ, Zuzana MICHALOVIČOVÁ-SNINSKÁ, Jaroslava VOGLOVÁ, Ludmila DEMITROVIČOVÁ, Eva MIKUŠOVÁ, Elena TÓTHOVÁ, Juraj CHUDEJ, Imrich MARKULJAK, Eduard CMUNT, Jana MORAVCOVÁ, Dana DVOŘÁKOVÁ, Kyra MICHALOVÁ, Marie JAROŠOVÁ, Markéta MARKOVÁ ŠŤASTNÁ, Petr CETKOVSKÝ, Ladislav DUŠEK, Vladimír KOZA, Marek TRNĚNÝ and Karel INDRÁK. Evaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cutoff levels. \textit{Cancer Medicine}. Houston: John Wiley \&{} Sons Ltd., 2013, vol.~2, No~2, p.~216-225. ISSN~2045-7634. Available from: https://dx.doi.org/10.1002/cam4.59.

Detailed Information on Publication Record